Grants and Contributions:
Title:
Feasibility Study for the Development of a Diamine Oxidase Powder
Agreement Number:
940271
Agreement Value:
$26,397.00
Agreement Date:
Dec 1, 2019 - Mar 31, 2021
Description:
Development of a stable powder version of a plant-based enzyme for the nutraceutical market
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4P 1P7
Reference Number:
172-2019-2020-Q4-940271
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
869485425
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days.
Amendment Date
Oct 1, 2020
Recipient's Operating Name:
Ibex Pharmaceuticals Inc
Recipient's Legal Name:
Ibex Pharmaceutiques Inc.
Federal Riding Name:
Mount Royal
Federal Riding Number:
24052
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
1111
Amendments: